Latanoprost

Latanoprost should be kept at room temperature, 15 C to 30 C (59 F to 86 F) and protected for direct light.

• How's Your Eye Health?
• Diabetes and Your Eyes
• Eye Care for Diabetes

• 13 Best Quit-Smoking Tips Ever
• What Stress Does to Your Mouth
• Healthy Home: To Buy or Not to Buy Organic?

• Frequent Constipation?
• Greater Food Accessibility

Latanoprost may cause increased brown pigmentation of the iris, which may be permanent. Eyelid skin darkening may occur, and may be reversible after discontinuation of latanoprost.

Eyelash changes may occur, including increased growth and thickness. Eyelash changes are usually reversible upon discontinuation of treatment.

Avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

If you develop an intercurrent ocular condition (e.g., trauma or infection) or have ocular surgery, you should immediately seek your doctor's advice concerning the continued use of the multiple-dose container.

If you develop any ocular reactions, particularly conjunctivitis and lid reactions, tell your doctor right away.

Latanoprost contains benzalkonium chloride, which may be absorbed by contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of latanoprost

If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

• tell your doctor if you are allergic to latanoprost or any other medicines.
• tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamin, and herbal supplements.
• tell your doctor if you have inflammation of the eye, and if you have or have ever had liver or kidney disease.
• tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while using latanoprost, call your doctor.

Storage

Ophthalmic

Unopened bottles: refrigerate at 2–8°C and protect from light.1 15

Opened bottles: room temperature (not exceeding 25°C) for up to 6 weeks.1

• Risk of changes in eyelashes and permanent darkening of iris, eyelashes, or skin around the eyes associated with therapy.1 Potential for disparity between eyes if only one eye is treated.1 36

• Importance of learning and adhering to proper administration techniques to avoid contamination of the solution with common bacteria that can cause ocular infections.1 Serious damage to the eye and subsequent loss of vision may result from using contaminated ophthalmic solutions.1

• Importance of informing clinicians if intercurrent ocular condition (e.g., trauma, infection) develops or ocular surgery is planned.1 Importance of immediately reporting ocular reactions, particularly conjunctivitis and eyelid reactions.1

• Importance of delaying insertion of contact lenses for at least 15 minutes after latanoprost instillation, since benzalkonium chloride preservative may be absorbed by soft lenses.1

• Importance of administering different topical ophthalmic preparations at least 5 minutes apart.1

• Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs.1

• Importance of women informing clinicians if they are or intend to become pregnant or plan to breast-feed.1

• Importance of informing patients of other important precautionary information. (See Cautions.)

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

• Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists.
• Use care when driving or doing other tasks that call for clear eyesight.
• Have your eye pressure checked. Talk with your doctor.
• Tell your doctor if you have an eye infection, eye injury, or will be having eye surgery.
• Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using latanoprost while you are pregnant.
• Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Eye irritation.
• Blurred eyesight.
• Burning.
• Stinging.
• Eyelash growth.
• Feeling that something is in the eye.
• This medicine may cause eyelash changes like dark eyelashes, thickness, or more eyelashes. Most of the time, these changes go back to normal after this medicine is stopped.

These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.

Refer to adult dosing.

One eye drop in the affected eye(s) once a day in the evening

Comments:
-If one dose is missed, treatment should continue with the next dose as normal.
-The dose should not exceed one drop in the affected eye(s) daily as more frequent administration may lessen the intraocular pressure lowering effect.
-Reduction of the intraocular pressure starts approximately 2 to 4 hours after the first administration with the maximum effect reached after 12 hours.
-This drug may be used concomitantly with other topical ophthalmic drugs to lower intraocular pressure.
-If more than one topical ophthalmic drug is being used, each one should be administered at least 5 minutes apart.

Use:
-Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Data not available